I agree that this site is using cookies. You can find further informations here.
X
García-Guiñon, A.
118  results:
Search for persons X
?
1

P512: PRELIMINARY RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 T..:

Bergua-Burgues, J. M. ; Rodríguez-Veiga, R. ; Cano, I....
HemaSphere.  6 (2022)  - p. 411-412 , 2022
Link: https://doi.org/10.1097/..
 
?
2

PACE as salvage therapy for relapsed or refractory multiple..:

Isola, I. ; Granell, M. ; Martí, J.M....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e300-e301 , 2015
Link: https://doi.org/10.1016/..
 
?
3

Renal Response in Patients (Pts) With Relapsed Refractory M..:

García-Guiñon, A. ; Morales, E. ; Escalante, F....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e289 , 2015
Link: https://doi.org/10.1016/..
 
?
4

Incidence of peripheral neuropathy in clinical practice in ..:

Garcia-Guiñon, A. ; Vicent, A. ; Escoda, L....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e205-e206 , 2015
Link: https://doi.org/10.1016/..
 
?
5

Disseminated histoplasmosis by Histoplasma capsulatum var. ..:

Garcia-Guiñon, A. ; Torres-Rodríguez, J. M. ; Ndidongarte, D. Torangar..
European Journal of Clinical Microbiology & Infectious Diseases.  28 (2008)  6 - p. 697-699 , 2008
Link: https://doi.org/10.1007/..
 
?
6

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN F..:

Tormo, Mar ; Diaz-Beya, Marina ; Beneit, Paola...
HemaSphere.  7 (2023)  S3 - p. e4025574 , 2023
Link: https://doi.org/10.1097/..
 
?
7

P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN..:

Garcia-Guiñon, Antonio ; Andrea Charry, Paola ; Moraima Jimenez, Maria...
HemaSphere.  7 (2023)  S3 - p. e81324da , 2023
Link: https://doi.org/10.1097/..
 
?
8

PB2123: ROLE OF INTERLEUKIN 6 AND ANGIOPOIETINS 1 AND 2 IN ..:

Upegui, Rosa Isabel ; Garcia-Guiñon, Antonio ; Arbonés, Xavier Gómez
HemaSphere.  7 (2023)  S3 - p. e8031195 , 2023
Link: https://doi.org/10.1097/..
 
?
9

P-161 Impact of induction treatment on the survival of pati..:

Santoja, Raquel ; Rivero, Eugenia ; Delgado, Izarbe...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S124 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Feasibility and outcomes after dose reduction of immunochem..:

Ribera, Josep-Maria ; Morgades, Mireia ; Garcia-Calduch, Olga...
Haematologica.  109 (2023)  2 - p. 543-552 , 2023
Link: https://doi.org/10.3324/..
 
?
11

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMU..:

Maria Ribera, Josep ; Morgades, Mireia ; García-Calduch, Olga...
HemaSphere.  7 (2023)  S3 - p. e813564b , 2023
Link: https://doi.org/10.1097/..
 
?
12

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL..:

Miguel Bergua Burgues, Juan ; Rodríguez-Veiga, Rebeca ; Cano Ferri, Isabel...
HemaSphere.  7 (2023)  S3 - p. e8385270 , 2023
Link: https://doi.org/10.1097/..
 
?
13

A glimpse into relapsed refractory multiple myeloma treatme..:

Ríos-Tamayo, Rafael ; Soler, Juan Alfons ; García-Sánchez, Ricarda...
Hematology.  28 (2023)  1 - p. , 2023
Link: https://doi.org/10.1080/..
 
?
14

Real-World Evidence of Daratumumab Monotherapy in Relapsed/..:

Moreno, David F. ; Clapés, Victoria ; Soler, Juan Alfons...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  8 - p. 635-642 , 2022
Link: https://doi.org/10.1016/..
 
?
15

European LeukemiaNet 2017 risk stratification for acute mye..:

Bataller, Alex ; Garrido, Ana ; Guijarro, Francesca...
Blood Advances.  6 (2022)  4 - p. 1193-1206 , 2022
Link: https://doi.org/10.1182/..
 
1-15